Navigation Links
CTI Issues Statement Regarding Tosedostat Clinical Trial
Date:6/24/2013

SEATTLE, June 25, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today issued the following statement regarding the notification of the U.S. Food and Drug Administration (the "FDA") partial clinical hold on tosedostat (IND 075503), the Company's aminopeptidase inhibitor under development for the treatment of blood-related cancers, that is being studied in an investigator-sponsored trial and not by CTI. CTI's primary development programs are the ongoing Phase 3 trial of pacritinib, the Company's JAK2/FLT3 inhibitor being evaluated for patients with myelofibrosis, and the post-approval commitment study of PIXUVRI® (pixantrone).

This is a partial clinical hold of only part of the clinical work requested under the investigational new drug ("IND") application. Under a partial clinical hold, although a specific protocol or part of a protocol is not allowed to proceed, other parts of such protocol or other protocols are allowed to proceed under the IND. With this partial clinical hold, the Company may not enter new patients onto any of the ongoing tosedostat protocols until agreement is reached with the FDA.

After a study has been placed on partial clinical hold, the sponsor provides additional information and discusses the adverse event with the FDA to understand whether or not it was associated with the drug or due to another cause. The Company has begun work to comply with the FDA request and expects to be able to submit these data to the FDA in the coming weeks. For additional information, please refer to the Current Report on Form 8-K filed by the Company on June 24, 2013.

Recent Tosedostat Publication
In March 2013, Lancet Oncology published results from the OPAL Phase 2 study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML). The trial showed that once-daily oral tosedostat resulted in a disease contro
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lilly Issues Alert for Illegal Scams Involving Fraudulent Checks and Online Job Requests
2. Celsion Corporation Issues Statement Regarding Misleading Blog Entry
3. Zydus Pharmaceuticals USA Inc. Issues Voluntary Nationwide Recall of Warfarin 2 mg Tablets, Lot MM5767, Expiration Date June 2014, Due to Oversized Tablets
4. Endeavor Power Corporation Issues Corrections on two of its earlier Press Releases dated January 9, 2013 and March 8, 2013
5. Neiman Center Issues Policy Brief Outlining Innovative Health Care Payment Models to Provide Cost-Effective Specialty Care for Patients
6. ISPE Patient Initiative Issues Survey Regarding Patient Experience with Clinical Materials
7. Ampio Pharmaceuticals Issues Statement Regarding Misleading Blog
8. American Academy of Ophthalmology Issues Statement on Provisions to Pharmaceutical Compounding Quality and Accountability Act
9. Royalty Pharma Issues Investor Presentation Highlighting The Strategic And Financial Advantages Of Its Offer To Acquire Elan For $12.50 Per Share In Cash
10. BD Issues 2012 Sustainability Report
11. TNI BioTech, Inc. Corporations CEO Issues Letter to Shareholders Discussing Recent Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... LAVAL, Quebec , March 27, 2015  Valeant ... announced today the closing of its previously announced registered ... States (the "Offering"). Pursuant to the Offering, ... of $199.00 per share, for aggregate gross proceeds of ... filed with the U.S. Securities and Exchange Commission a ...
(Date:3/27/2015)... , March 27, 2015   Hospira, ... leader in biosimilars and the world,s leading provider ... studies that support an evaluation of biosimilarity of ... Food and Drug Administration (FDA) conditionally approved name ... EPOGEN™ (epoetin alfa). These study data were presented ...
(Date:3/27/2015)...  Delcath Systems, Inc. (NASDAQ: DCTH ), ... on oncology with an emphasis on the treatment ... reporting of data from a single -center experience ... the Delcath Hepatic Delivery System (Melphalan/HDS) and other ... of Surgical Oncology (SSO) Annual Meeting 2015.  The ...
Breaking Medicine Technology:Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5
(Date:3/28/2015)... Early surgery may not be the ... joint injuries, according to new research from Tripler Army ... Orthopaedic Society for Sports Medicine’s ( AOSSM ) Specialty ... surgery was not performed. , The final study group ... and 17 receiving non-surgical therapy. Of the non-surgery group, ...
(Date:3/28/2015)... Lately the student-athlete experience has ... proposals around the NCAA. In a March episode of ... across a spectrum of universities and sports shed light ... special panel consists of athletes who have competed for ... track and field, baseball, and volleyball. They discuss the ...
(Date:3/28/2015)... 28, 2015 The "Petrick Sustainable ... sustainable health. After 18 years of research and experience ... UFC contenders, Dr. Jon Petrick is excited to be ... some of the immediate benefits of this radical new ... levels of strength of the immune system, faster healing ...
(Date:3/28/2015)... Plainview, NY (PRWEB) March 28, 2015 ... provider of dietary supplements announces the release of ... MuffinStop™ was shown in two randomized, double-blind, placebo-controlled ... weight and waist and hip size. MuffinStop™ is ... Sphaeranthus indicus and Garcinia mangostana, fused together to ...
(Date:3/27/2015)... FL (PRWEB) March 27, 2015 The ... guide from dating experts Samantha Sanderson and Jason Rogers ... frenzied buzz of media attention. The commotion surrounding the ... Roman, prompting him to publish an in-depth review of ... devastated when the men in their lives suddenly start ...
Breaking Medicine News(10 mins):Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 3Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2
... Treuman Katz Center for Pediatric Bioethics at Seattle Children,s ... Conference on Friday, July 22 and Saturday, July 23. ... policy boundaries and complexities of providing healthcare to children. ... the Boundaries of Clinical Ethics and Public Policy," will ...
... HealthDay Reporter , WEDNESDAY, July 20 (HealthDay ... skin rashes, but the similarities between the two common, ... examining patients suffering from both ailments (a very rare ... system responses that prompt skin flare-ups for both diseases. ...
... , WEDNESDAY, July 20 (HealthDay News) -- The ... their patients, health, new research indicates. It also plays ... errors and patient satisfaction, according to a commentary in the ... who are civil, the report claimed, can more effectively help ...
... HealthDay Reporter , WEDNESDAY, July 20 (HealthDay News) ... be heating up. New technology promises to cut costs while ... of your genes and potentially provide a personalized report of ... The human genome was first mapped in 2001 and cost ...
... cascade of chemistry to stem the flow of blood. Now, ... have used evolutionary clues to reveal how a key clotting ... disorders. The long tube-shaped protein with a vital role ... in cells that form the inner lining of blood vessels, ...
... , In the fight to improve global health, alleviate ... developing world, chickens have an important role to play. ... Center for Infectious Diseases and Vaccinology at Arizona State ... a more productive species of chicken for villagers in ...
Cached Medicine News:Health News:Exploring the limits of children's health care: What's the reality of providing care to all? 2Health News:Scientists Close in on Origins of Psoriasis, Eczema 2Health News:Scientists Close in on Origins of Psoriasis, Eczema 3Health News:Rude Surgeons Hurt Patients, Increase Costs 2Health News:Cheaper DNA Sequencing Coming Closer 2Health News:Cheaper DNA Sequencing Coming Closer 3Health News:Evolution provides clue to blood clotting 2Health News:Evolution provides clue to blood clotting 3Health News:A new breed: Highly productive chickens help raise Ugandans from poverty 2Health News:A new breed: Highly productive chickens help raise Ugandans from poverty 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: